Clinical trials
Phase 2 trials in Lebanon
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
87 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 14 |
| 2019 | 7 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
| Terminated | 15 |
| Unknown status | 9 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 15 |
| American University of Beirut Medical Center | 11 |
| Pfizer | 4 |
| EMD Serono | 3 |
| GlaxoSmithKline | 3 |
| Hoffmann-La Roche | 3 |
| AstraZeneca | 2 |
| Cardurion Pharmaceuticals, Inc. | 2 |
| Celgene | 2 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Sickle Cell | 17 |
| beta-Thalassemia | 12 |
| Thalassemia | 8 |
| Iron Overload | 6 |
| Breast Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Amyotrophic Lateral Sclerosis | 2 |
| Anemia | 2 |
| Epilepsy | 2 |
| Genetic Diseases, Inborn | 2 |
Trials
Showing 76 to 87 of 87. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.